SGM
DYN icon

Seven Grand Managers’s Dyne Therapeutics DYN Stock Holding History

Seven Grand Managers’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$635K Hold
35,000
– – 0.04% 163
2025
Q4 		$685K Buy
+35,000
New +$663K 0.05% 136

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Seven Grand Managers's DYN Position: Q1 2026 in Review

Seven Grand Managers held its Dyne Therapeutics (DYN) position steady in Q1 2026 at 35,000 shares worth $635K. The position accounts for 0.04% of the portfolio, ranked #163.

Seven Grand Managers first reported a position in DYN in Q4 2025 and has held it in 2 quarters since. The position peaked at $685K in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Seven Grand Managers held 35,000 shares of Dyne Therapeutics worth $635K as of Q1 2026.
  • Seven Grand Managers left its Dyne Therapeutics share count unchanged in Q1 2026.
  • Dyne Therapeutics made up 0.04% of Seven Grand Managers's portfolio in Q1 2026, its #163 holding.
  • Seven Grand Managers first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Seven Grand Managers's Dyne Therapeutics position peaked at $685K in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Seven Grand Managers's 13F filing for Q1 2026, filed 6 May 2026.